1. Home
  2. ACET vs VATE Comparison

ACET vs VATE Comparison

Compare ACET & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$7.29

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

N/A

Current Price

$4.99

Market Cap

74.0M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
VATE
Founded
1947
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
74.0M
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
ACET
VATE
Price
$7.29
$4.99
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$65.33
N/A
AVG Volume (30 Days)
134.8K
11.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
59.82
N/A
EPS
N/A
N/A
Revenue
N/A
$1,107,100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$4.05
52 Week High
$9.05
$9.01

Technical Indicators

Market Signals
Indicator
ACET
VATE
Relative Strength Index (RSI) 52.48 44.56
Support Level $6.54 $4.80
Resistance Level $8.46 $5.37
Average True Range (ATR) 0.46 0.22
MACD -0.01 -0.02
Stochastic Oscillator 49.12 26.38

Price Performance

Historical Comparison
ACET
VATE

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.

Share on Social Networks: